Centre Georges Francois Leclerc

This study tests whether adding a short course of the MEK inhibitor mirdametinib to standard chemoimmunotherapy is safe and effective for people with advanced non-squamous non-small cell lung cancer whose PDL1 level is below 50%. About 24 participants will first help find the bes…

This study aims to find out if a more detailed genetic analysis of tumors can help doctors choose better treatments for people with advanced cancer. About 8,000 adults with metastatic or locally advanced solid tumors will have their tumor DNA analyzed in two ways: a standard test…

This study looks for new genetic causes of cancer in people diagnosed at a young age (under 40, or under 30 for breast cancer). Standard genetic tests often miss the cause, so researchers will use a more detailed method called exome sequencing to search for hidden risk factors. T…